This trial is testing the hypothesis that carnitine supplementation can improve RV function in PAH patients by measuring the oral consumption of carnitine, the stability of plasma carnitine levels, and the effects of carnitine supplementation on RV function.
- Pulmonary Arterial Hypertension
- Lung Disease
- Familial Primary Pulmonary Hypertension
- Primary Pulmonary Hypertension
- Carnitine Deficiency
1 Primary · 7 Secondary · Reporting Duration: 14 weeks
Side Effects for
1 Treatment Group
1 of 1
12 Total Participants · 1 Treatment Group
Primary Treatment: L-carnitine · No Placebo Group · Phase 1
Who is running the clinical trial?
Age 18 - 85 · All Participants · 6 Total Inclusion CriteriaMark “Yes” if the following statements are true for you:
Frequently Asked Questions
Has L-carnitine been granted authorization by the Food and Drug Administration?
"While data exists to suggest that L-carnitine is effective and safe, due to this being a Phase 1 trial we have given it the lowest possible rating of '1' on our scale." - Anonymous Online Contributor
What is the upper bound on enrollment for this medical experiment?
"Affirmative. Clinicaltrials.gov's records demonstrate that this medical experiment, which went public on September 29th 2021 is actively asking for volunteers. A total of 12 individuals will be chosen from a single location for participation in the trial." - Anonymous Online Contributor
Is there an age limit for individuals wishing to participate in the research trial?
"As stated in the study's eligibility requirements, individuals aged 18 to 85 are able to enroll." - Anonymous Online Contributor
Are they admitting new participants in this experiment?
"As stated on clinicaltrials.gov, this medical experiment is currently recruiting participants. It was first made available on September 29th 2021 and the most recent modifications to it took place on August 30th 2022." - Anonymous Online Contributor
Is it possible to enlist as a participant in this trial?
"This trial is seeking 12 volunteers who are aged 18 to 85, have a diagnosis of lung disease and meet some essential criteria. These include: (1) having been on a stable PAH-specific medication regime for 3 months; (2) no more than one adjustment in diuretics within the same time period; (3) IV prostacyclin readjustment permissible if side effects occur; (4) ambulatory ability and WHO Functional Class II-IV status." - Anonymous Online Contributor